Elacestrant

Elacestrant (RAD1901), sold under the brand name Orserdu, is an anticancer medication which is used in the treatment of breast cancer and has recently been approved by the FDA (January 2023). Elacestrant is an investigational selective estrogen receptor degrader (SERD), out-licensed to Menarini Group (developed by Radius Health, Inc), which is used as a once daily oral treatment in patients with ER+/ HER2- advanced breast cancer. This is not the first time the two companies worked together, in 2020, Menarini Group acquired the exclusive rights to commercialize Eladynos, a new drug developed by Radius Health for the treatment of osteoporosis, in Europe, the Middle East, and Africa. Under the terms of the agreement, Menarini Group will be responsible for obtaining regulatory approvals, launching the drug, and promoting it in these regions. In exchange, Radius Health will receive an upfront payment, as well as royalties on sales generated by Menarini Group.